Evidence map›Paper›PMID 36419513›Full record

ArticleAnnals of neurosciences2022

Use of Ceftriaxone as a Predictor of Good Outcome in Stroke Patients: A Retrospective Chart Review.

Priya Dev, Varun Kumar Singh, Anand Kumar, Rameshwar Nath Chaurasia, Neelima Alka Singh, Priyanka Gautam, Neetu Rani Dhimani, Vijaya Nath Mishra, Deepika Joshi, Abhishek Pathak

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Priya DevDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.ORCID https://orcid.org/0000-0003-2413-7071
Varun Kumar SinghDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Anand KumarDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Rameshwar Nath ChaurasiaDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.ORCID https://orcid.org/0000-0002-5697-8804
Neelima Alka SinghCollege of Nursing, Sir Sunderlal Hospital, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Priyanka GautamDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Neetu Rani DhimaniDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Vijaya Nath MishraDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Deepika JoshiDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.ORCID https://orcid.org/0000-0002-5224-2808
Abhishek PathakDepartment of Neurology, Institute of Medical Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Banaras Hindu University · INSir Sunderlal Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Whether ceftriaxone (CEFT) has any added advantage other than its antibiotics effect in stroke as a neuroprotective agent is not known, and this forms the base of this study. Purpose: We tried to assess the predictive role of the use of CEFT with respect to outcome in stroke patients. Methods: A retrospective chart review was conducted from a stroke registry over consecutive stroke patients admitted at a tertiary teaching institute from January 2017 to December 2018. Patients were categorized into three groups on the basis of antibiotics they received; patients without antibiotic treatment (NAB), piperacillin plus tazobactam treatment, and the CEFT treatment group. The outcome was assessed by the modified Rankin Scale at three months in good (0-3) and poor outcomes (4-6). Results: A total of 390 stroke patients were analyzed with ages ranging between 20 and 95 years and 151 of them were females. It was found that the severity at three months was significantly lower in those patients who were given CEFT antibiotic ( Conclusion: Stroke patients in CEFT-treated group have a better outcome compared to piperacillin-tazobactam therapy or without antibiotics use at three months. This study indicates the possibility of an additional neuroprotective effect of CEFT apart from its antibacterial property.

Indexed as

CeftriaxonemRSNeuroprotectionPiperacillin–tazobactamStroke

Identifiers

PMID36419513
PMCPMC9676337
OpenAlexW4225724269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.